Mologen Shares Rise on Cancer Immunotherapy Phase II Data
By Cormac Sheridan
Wednesday, May 16, 2012
Shares in Mologen AG jumped 17 percent to a 52-week high Monday on news that the company's DNA-based cancer immunotherapy, MGN1703, hit the primary endpoint, a prolongation of progression-free survival (PFS), in a Phase II trial in patients with metastatic colorectal cancer (CRC).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.